In conclusion, H4R agonists are a crucial component of the pathology of MS and EAE experimental models, and additional research is required to elucidate the molecular mechanisms underlying the neuroinflammatory effects of H4R agonists. This evidence concerns the gene HRH4 and myeloid sarcoma.